The core product of Disulfican is PLGA encapsulated Disulfiram microparticles (PLGA-DS-MPs) which is suitable for local injection and hence used to target cancers via the local delivery/injection. Considering the nature of locally penetrating/infiltrating nature of malignant mesothelioma in the chest and abdominal cavities and relatively rare metastasis, Disulfican has taken the approach to progress our proprietary PLGA-DS formulation as a novel treatment for Malignant Mesothelioma via intrapleural or intraperitoneal delivery. Our local injection strategy will avoid the degradation and metabolism of Disulfiram in the liver and retain its anticancer profile.

We can extend the use of locally administered PLGA Disulfiram to treat other types of cancers such as glioblastoma or for the treatment of pleural or peritoneal metastasis of solid cancers such as breast cancer, lung cancer, bowel cancer and ovarian cancer.

In addition to PLGA Disulfiram, Disulfican’s work addresses the development of other novel formulations of disulfiram and its metal complex derivatives for treatment of other aggressive cancers such as Pancreatic cancer, non-small cell lung cancer and Multiple Myeloma. We have a proprietary formulation pipeline that can be used effectively on different cancers based on different routes of administration. Disulfican has developed a very promising proof of concept results using animal models and patient derived primary cells for these cancers.